Market Access Views & Analysis

Views & Analysis

Creating sustainable access to modern medicine

It’s easy to overlook just how much the world has changed in healthcare terms over the last 40-50 years thanks to modern medicine. From the availability of antibiotics to the trans

Views & Analysis

Janssen: ‘Open dialogue’ needed with HTAs to improve access

The world of life sciences is changing rapidly, and the traditional ways of assessing drugs may no longer be fit for purpose.

Views & Analysis

The unprecedented challenge of pricing a coronavirus vaccine

The optimal pricing strategy for a new vaccine involves setting a fair and sustainable price that enables the eligible population in need across the world to gain access, while also rewardi

Views & Analysis

A novel approach to detecting Alzheimer’s early

The grey matter in the brain may hold vital clues for early, accurate detection in Alzheimer’s, and potentially also help pharma to find new drug treatments.

Views & Analysis

Improving access and reimbursement for specialty therapies

As specialty therapies move toward long-term maintenance use and as treatment times grow longer, government and commercial payers are scrutinising the economic value of new treatments more

Views & Analysis

Market access in the time of COVID-19

COVID-19 has left no part of life untouched, including health technology assessment (HTA) and other payer agency activities, and it will likely have a lasting impact on market access.

Creating sustainable access to modern medicine

Janssen: ‘Open dialogue’ needed with HTAs to improve access

The unprecedented challenge of pricing a coronavirus vaccine

A novel approach to detecting Alzheimer’s early

Improving access and reimbursement for specialty therapies

Market access in the time of COVID-19

Getting predictive technologies to patients, with Concr

Discover a new era of healthcare panel engagement: Grounded ...

Views & Analysis

Editor's Picks